DDX5 and neoplasm: By contrast, xenograft tumors from Dox-fed animals treated with sorafenib exhibited sustained DDX5 protein levels, absence of GPX4 induction (Fig. 8A), and reduced tumor weight in comparison to those without Dox administration (Fig. 8B and Supplementary Fig. S8B).